oa Ruthenium in Medicine: Current Clinical Uses and Future Prospects

References

1. M. J. Clarke, F. Zhu, D. R. Frasca,, and , ‘Non-platinum chemotherapeutic metallopharmaceuticals’, Chem. Rep., 1999, 99, 2511-2534 [Google Scholar]
2. Z. Guo, P. J. Sadler, and , ‘Medicinal inorganic chemistry’, Adv. lnorg. Chem., 1999, 49, 183-306 [Google Scholar]
3. G. Sava, E. Alessio, A. Bergamo, G. Mestroni,M. J. Clarke, P. J. Sadler,, , and , ‘Sulfoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumor metastases’, in “Metallopharmaceuticals I, DNA Interactions”, eds. and , Springer-Verlag, Berlin, 1999, pp. 143-169 [Google Scholar]
4. A. Eastman,B. Lippert,, ‘The mechanism of action of cisplatin: from adducts to apoptosis’, in “Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug”, ed. , Wiley-VCH, Weinheim, 1999, pp. 111-134 [Google Scholar]
5. M. J. Abrams, B. A. Murrer, and , Science, 1993, 261, 725—730 (A general reference on metals in medicine) [Google Scholar]
6. S. P. Fricker,A. Siegel, H. Siegel,, ‘Nitrogen monoxide-related disease and nitrogen monoxide scavengers as potential drugs’, in “Metal Ions in Biological Systems”, Volume 36, eds. and , Marcel Dekker Inc., New York, 1999, pp. 665-721 (A review on metal compounds and nitric oxide focusing on ruthenium compounds) [Google Scholar]
7. M. J. Abrams,, ‘Ruthenium Phthalocyanines’, Platinum Metals Rev., 1995, 39, (1), 14-18 [Google Scholar]
8. S. P. Fricker,, ‘Ruthenium, Nitric Oxide and Disease’, Platinum Metals Rev., 1995, 39, (4), 150-159 [Google Scholar]